<div id="readability-page-1"><p>Donoghue Forlines LLC purchased a new position in  Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 8,934 shares of the company's stock, valued at approximately $1,482,000.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>3 Big Dividend Plays With Strong Earnings to Back Them</li></ul><p>Several other institutional investors have also added to or reduced their stakes in the business. Highline Wealth Partners LLC increased its stake in shares of  Johnson &amp; Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter.  von Borstel &amp; Associates Inc. purchased a new position in  Johnson &amp; Johnson during the first quarter valued at $49,000.  Capital A Wealth Management LLC purchased a new position in  Johnson &amp; Johnson during the fourth quarter valued at $50,000.  Harvest Fund Management Co. Ltd purchased a new position in  Johnson &amp; Johnson during the first quarter valued at $52,000.  Finally, Accredited Wealth Management LLC purchased a new position in  Johnson &amp; Johnson during the fourth quarter valued at $58,000. 69.55% of the stock is currently owned by institutional investors. </p><h2>Johnson &amp; Johnson Trading Up 1.1%</h2><p>Shares of JNJ opened at $173.40 on Friday. Johnson &amp; Johnson has a 1-year low of $140.68 and a 1-year high of $173.96. The company has a 50-day moving average of $159.26 and a 200 day moving average of $157.44. The firm has a market capitalization of $417.61 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. </p><ul><li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis.  On average, research analysts expect that  Johnson &amp; Johnson will post 10.58 EPS for the current year. </p><h2>Johnson &amp; Johnson Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise</li></ul><p>Several equities analysts recently weighed in on the stock. Bank of America raised their target price on shares of Johnson &amp; Johnson from $161.00 to $175.00 and gave the company a &#34;neutral&#34; rating in a research note on Thursday, July 17th. UBS Group raised their target price on shares of Johnson &amp; Johnson from $180.00 to $190.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, July 17th. Barclays raised their target price on shares of Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Piper Sandler  reaffirmed an &#34;overweight&#34; rating on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Finally, Leerink Partnrs cut shares of Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued  a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $174.50.</p><p><b>View Our Latest Report on Johnson &amp; Johnson</b></p><h2>Johnson &amp; Johnson Company Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>The 3 Best Retail Stocks to Shop for in August</li><li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li><li>How to Use the MarketBeat Dividend Calculator</li><li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li><li>Procter &amp; Gamble <span>NYSE: PG<span></span></span> Pulls Back After Shaky Guidance</li><li>Viasat: Why a Wall of Cash Has Shorts Running for Cover</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Donoghue Forlines LLC has made a new investment of approximately $1.48 million in Johnson & Johnson (NYSE:JNJ), acquiring 8,934 shares during the first quarter. Other institutional investors have also adjusted their stakes in the company. Johnson & Johnson's stock is currently trading at $173.40, with a market cap of $417.61 billion. The company recently reported earnings of $2.77 per share, exceeding estimates, and announced a quarterly dividend of $1.30 per share. Analysts have varied ratings on the stock, with a consensus target price of $174.50.</p>

Donoghue Forlines LLC Makes New $1.48 Million Investment in Johnson & Johnson (NYSE:JNJ)